|
Drug supply levels are above demand, say manufacturers Manufacturers have hit back at allegations of short supply, with figures suggesting drug supply to the UK is greater than demand.
Responding to reports from wholesalers that they are unable to source key drugs, industry body the Association of the British Pharmaceutical Industry (ABPI) released an analysis suggesting drug supply is in excess.
Stock shortages were instead caused by 11 per cent of pharmacies “exploiting the system” by diverting UK medicines abroad in a trade worth £30 million a month, the
“The reality is that medicines produced for UK patients are being removed from the UK supply chain,” the ABPI commented.
According to IMS data, supply of Xenical, Zyprexa and Cipralex – the three medicines pharmacists reported most difficult to source in the C+D Stock Survey last week – exceeded estimated demand by 8 per cent, 13 per cent and 10 per cent respectively. Supply of immunosuppressant Myfortic, another drug mentioned as being in short supply, was shown to exceed demand by 65 per cent.
Emergency supplies of medicines by three manufacturers between January and May increased by 1,156 per cent compared with the same period last year, the ABPI added.
Last month the British Association of Pharmaceutical Wholesalers reported members were unable to supply up to eight in 10 pharmacies because they could not source stock from manufacturers. |
RELATED ARTICLES Use emergency powers to solve drugs shortages, government told > Medicine exporters could face prosecution, guidance warns > Medicine supply guidance published > Guidance to ease stock shortages imminent > DH pledges action to tackle stock shortages > C+D conference: Crisis talks over drug shortages under way > AAH: ministers hold key to solving stock shortages > AAH chief: clear stance needed on parallel trade > Take action to ease shortages, drug firms told > C+D stock survey: Xenical, Zyprexa and Cipralex top list of shortages > |
||